Madhuri Vusirikala MD
Hematologic Oncology
Professor, Internal Medicine, University of Texas Southwestern Medical Center, Southwestern Medical School
Join to View Full Profile
2201 Inwood RdDallas, TX 75235
Phone+1 214-645-4673
Dr. Vusirikala is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1996 - 1999
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1993 - 1996
Lady Hardinge Medical CollegeClass of 1992
Certifications & Licensure
TX State Medical License 2006 - 2025
TN State Medical License 2000 - 2006
PA State Medical License 1996 - 2000
WI State Medical License 1995 - 1997
Clinical Trials
- A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) Start of enrollment: 2022 Jun 16
Roles: Contact
Publications & Presentations
PubMed
- Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.Sameem M Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C Michaelis, Karen-Sue Carlson
Leukemia. 2025-02-15 - 1 citationsRandomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2025-01-10 - Anti-Spike Antibody Responses in Allogeneic Stem Cell Transplant Recipients to Two Doses of COVID-19 mRNA Vaccination: A Retrospective, Single-Center Analysis.Jaime L Shahan, Robert H Collins, Prapti Patel, Yazan F Madanat, Madhuri Vusirikala
Journal of the Advanced Practitioner in Oncology. 2023-07-01
Press Mentions
Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-AOctober 27th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
